Switch theme
Sign up to access all valuation multiples
Vistin Pharma ASA is a Norway based pharmaceutical company. It is principally engaged in the business activity of producing active pharmaceutical ingredients (APIs) and solid dosage forms for the pharmaceutical industry. The company has two business segments namely Pharmaceuticals and Energy Trading. The group has operations in Norway, Germany, Switzerland, Great Britain, Algeria and other countries.
2015
75
Last FY Revenue $41.9M
Last FY EBITDA $10.0M
$111M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Vistin Pharma achieved revenue of $41.9M and an EBITDA of $10.0M.
Vistin Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vistin Pharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $41.9M | XXX | XXX | XXX |
| Gross Profit | XXX | $21.0M | XXX | XXX | XXX |
| Gross Margin | XXX | 50% | XXX | XXX | XXX |
| EBITDA | XXX | $10.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 24% | XXX | XXX | XXX |
| EBIT | XXX | $8.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | 20% | XXX | XXX | XXX |
| Net Profit | XXX | $6.1M | XXX | XXX | XXX |
| Net Margin | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Vistin Pharma's stock price is NOK 26 (or $3).
Vistin Pharma has current market cap of NOK 1.2B (or $113M), and EV of NOK 1.1B (or $111M).
See Vistin Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $111M | $113M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Vistin Pharma has market cap of $113M and EV of $111M.
Vistin Pharma's trades at 2.7x EV/Revenue multiple, and 11.2x EV/EBITDA.
Equity research analysts estimate Vistin Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vistin Pharma's P/E ratio is not available.
See valuation multiples for Vistin Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $113M | XXX | $113M | XXX | XXX | XXX |
| EV (current) | $111M | XXX | $111M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 11.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 13.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 18.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 17.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVistin Pharma's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.2M for the same period.
Vistin Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vistin Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vistin Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vistin Pharma acquired XXX companies to date.
Last acquisition by Vistin Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Vistin Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vistin Pharma founded? | Vistin Pharma was founded in 2015. |
| Where is Vistin Pharma headquartered? | Vistin Pharma is headquartered in Norway. |
| How many employees does Vistin Pharma have? | As of today, Vistin Pharma has 75 employees. |
| Who is the CEO of Vistin Pharma? | Vistin Pharma's CEO is Mr. Magnus Tolleshaug. |
| Is Vistin Pharma publicy listed? | Yes, Vistin Pharma is a public company listed on OSL. |
| What is the stock symbol of Vistin Pharma? | Vistin Pharma trades under VISTN ticker. |
| When did Vistin Pharma go public? | Vistin Pharma went public in 2015. |
| Who are competitors of Vistin Pharma? | Similar companies to Vistin Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vistin Pharma? | Vistin Pharma's current market cap is $113M |
| Is Vistin Pharma profitable? | Yes, Vistin Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
